Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in pediatric melanoma
NCT01696045Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in Malignant Melanoma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall Survival Rate at 1 Year and Percentage of Participants With Severe Immune-Mediated Adverse Reactions. Started Nov 2012; status: terminated.
02
Drugs
ipilimumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01696045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696045.